Seaforth Energy Inc. Secures $1.9M Atlantic Innovation Fund Investment

Seaforth Energy Inc., a leading wind turbine manufacturer and renewable energy integrator, will receive $1.9 million from the Atlantic Canada Opportunities Agency (ACOA) under the Atlantic Innovation Fund (AIF) to develop new wind turbines.

The funding will be used towards Seaforth Energy’s $2.9 million R&D project already underway to extend its proven AOC turbine product line.

Immunovaccine Receives $2.9M from ACOA

Immunovaccine Inc. (TSX-V: IMV), a clinical stage vaccine developer, will receive $2.9 million from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF).

This non-dilutive funding will enable Immunovaccine to develop new diagnostics to identify specific subsets of cancer patient populations that would benefit most from receiving DepoVax™-based vaccine therapies. This funding will also help the company develop additional methods for measuring vaccine activity, information that will help the company design future Phase II clinical trials.

Innovacorp Launches Science and Technology Advisory Council

Early stage technology companies in the province are getting improved access to scientific and technology expertise thanks to Innovacorp's new advisory council.

"I'm delighted to have a group of this calibre as a resource for us and our clients," said Clifford Gross, president and CEO of Innovacorp. "Their experience, knowledge of science and industry, and contacts in the global community will be invaluable.

"The council will also be a great platform for assessing emerging science and technology issues important to Nova Scotia's economic future."

Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens

Immunotope Inc. and Immunovaccine Inc. (TSX-V:IMV) announced today that the U.S. Patent and Trademark Office has issued an official Notice of Allowance for a new U.S. Patent specific to the DPX-0907 therapeutic cancer vaccine.The new U.S. patent application titled “Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer” provides additional intellectual property protection in the U.S. for the seven antigens used in Immunovaccine’s DPX-0907, a therapeutic cancer vaccine for patients with breast, ovarian or prostate cancers.

2011-2012 I-3 Technology Start-Up Competition

Innovacorp's I-3 Technology Start-Up Competition is back!

In the coming weeks, we'll be searching Nova Scotia for new knowledge-based companies with cutting-edge products and services. We'll launch the competition at the following locations across the province starting in mid September.

Zone 4 (Halifax Regional Municipality) launch
Tuesday, September 13, 11:00 am
Innovacorp Enterprise Centre
1344 Summer St., Halifax

Canadian Innovation Commercialization Program Helps Kickstart Businesses

The Honourable Rona Ambrose, Minister of Public Works and Government Services and Minister for Status of Women, today (Feb. 4) met with a group of entrepreneurs and industry leaders from across Canada who will use their private sector expertise to select the recipients of funding under the Canadian Innovation Commercialization Program (CICP).

Innovacorp's vice president of investment, Ben Forcier, is a selection committee member.

Equals6 Adds Top-Tier Executives

Equals6, the Halifax-based student career development network, announced the appointment of three new executive team members today.

Joining Equals6 are John Gibbons as vice president of sales, April Macleod as vice president of customer care, and Michael Sanderson as vice president of education and training.

“This is an exciting time for Equals6. John, April and Michael bring proven expertise and passion to lead the rapid growth and expansion of Equals6,” said Andy Osburn, CEO of Equals6.


Subscribe to Innovacorp RSS